Multiple endocrine neoplasia (MEN) is a group of inherited conditions that cause tumors to develop in two or more hormone-producing glands. These tumors can appear in the parathyroid glands, thyroid, pancreas, pituitary gland, or adrenal glands, depending on the type. MEN comes in several forms, each linked to a specific gene mutation passed from parent to child in an autosomal dominant pattern, meaning a single copy of the faulty gene from one parent is enough to cause the condition.
The Main Types of MEN
There are three primary patterns: MEN1, MEN2 (which itself has subtypes 2A and 2B), and the more recently identified MEN4. Each type targets a different combination of glands and carries different risks. The types don’t progress into each other. Which type you have depends entirely on which gene is affected, and that determines which glands are vulnerable to tumor growth throughout your lifetime.
MEN1 has an estimated prevalence of roughly 1 in 20,000 to 1 in 40,000 people. MEN2A is the most common form of MEN2, while MEN2B accounts for only 5 to 10 percent of all MEN2 cases but is the most aggressive.
MEN1: Parathyroid, Pancreas, and Pituitary
MEN1 is sometimes called the “three Ps” syndrome because it primarily affects the parathyroid glands, the pancreas, and the pituitary gland. It’s caused by mutations in the MEN1 gene, which normally acts as a tumor suppressor. When this gene is faulty, cells in those glands can grow unchecked.
Parathyroid tumors are by far the most common feature. About 95 percent of people with MEN1 develop parathyroid tumors by age 50, leading to excess calcium in the blood (hyperparathyroidism). This can cause fatigue, kidney stones, bone thinning, and confusion. Around 40 percent develop tumors in the pancreas or other parts of the digestive tract. These tumors sometimes produce excess hormones like insulin or gastrin, which can cause low blood sugar episodes or severe stomach ulcers. Nearly 1 in 3 people with MEN1 develop a tumor in the front part of the pituitary gland, which may overproduce hormones like prolactin or growth hormone, leading to symptoms ranging from menstrual changes and headaches to abnormal growth patterns.
Not all MEN1 tumors are cancerous. Many are benign but still cause problems because they churn out excess hormones that throw the body off balance.
MEN2: Thyroid Cancer and Adrenal Tumors
MEN2 is driven by mutations in the RET gene and centers on medullary thyroid carcinoma (MTC), a cancer arising from specialized cells in the thyroid. Nearly 100 percent of people with MEN2A or MEN2B will develop this cancer or its precursor if left untreated.
MEN2A
In MEN2A, medullary thyroid cancer is typically multifocal, meaning it appears in multiple spots within the thyroid, and often affects both sides. About 50 percent of MEN2A patients develop pheochromocytomas, which are tumors of the adrenal glands that can trigger dangerously high blood pressure, rapid heartbeat, and severe headaches. These adrenal tumors frequently affect both glands, though not always at the same time. Around 20 to 30 percent also develop overactive parathyroid glands. The thyroid cancer in MEN2A tends to peak in the second and third decades of life, and while it can spread, it often behaves in a relatively slow-growing fashion. Ten-year overall survival is around 92 percent with appropriate treatment.
Some MEN2A patients also develop cutaneous lichen amyloidosis, an itchy, rough skin patch on the upper back that can actually appear before any thyroid cancer is detected.
MEN2B
MEN2B is the rarest subtype but the most dangerous. Medullary thyroid cancer develops earlier (often in the first or second decade of life) and behaves more aggressively, with deaths from metastatic disease reported even in young children. Before the era of early preventive surgery, the average age at death for MEN2B patients was just 21 years. About 45 to 50 percent develop pheochromocytomas, but parathyroid disease is essentially absent in this subtype.
MEN2B also has distinctive physical features that can be visible from infancy. Patients develop small, painless bumps called mucosal neuromas on the lips, tongue, and eyelids. They often have a tall, slender body type with unusually flexible joints. Widespread nerve tissue overgrowth in the gut leads to digestive problems, and infants or young children with MEN2B may present with chronic diarrhea, constipation, or a condition resembling megacolon. Recognizing these physical features early is critical, because immediate surgical intervention gives the best chance of survival.
MEN4: A Newer, Milder Variant
MEN4 was identified more recently and is caused by mutations in the CDKN1B gene rather than the MEN1 gene. Its symptoms overlap considerably with MEN1, involving parathyroid tumors, pituitary tumors, and pancreatic tumors. However, MEN4 generally appears later in life and is less severe. The average age when the first tumor shows up is about 43.5 years, compared to roughly 32 years in MEN1. Multiple gland involvement and recurrent parathyroid disease are much less common: only about 14 percent of MEN4 patients develop disease in multiple parathyroid glands, and just 6 percent have recurrent disease.
Pituitary tumors in MEN4 tend to be the type that produces excess stress hormones (ACTH-secreting adenomas), which differs from the prolactin-secreting tumors more common in MEN1. Pancreatic tumors in MEN4 also tend to appear later, with the youngest reported case diagnosed at age 42.
How MEN Is Diagnosed
Diagnosis typically starts when a person develops tumors in two or more endocrine glands, or when a single endocrine tumor appears in someone with a family history of MEN. The process combines family history, physical examination, hormone blood tests, and genetic testing.
Blood tests can detect hormone imbalances caused by tumors years before the tumors themselves become visible on imaging. For MEN1, biochemical screening can pick up the disease roughly 5 to 8 years before symptoms appear. This includes checking blood calcium and parathyroid hormone levels yearly, along with markers for pancreatic and pituitary tumors. Imaging like CT scans, MRI, and endoscopic ultrasound is used to locate and monitor tumors once hormone levels become abnormal.
Genetic testing provides a definitive answer. For MEN1, this involves analyzing the MEN1 gene’s coding regions for mutations. For MEN2, the RET gene is tested. If neither gene shows a mutation in someone who looks like they have MEN1, the CDKN1B gene is checked to rule out MEN4. Genetic testing is especially important for family members who haven’t developed symptoms yet, because it identifies carriers who need lifelong surveillance.
Family Screening and Early Intervention
Because MEN syndromes follow an autosomal dominant inheritance pattern, each child of an affected parent has a 50 percent chance of carrying the mutation. Current guidelines recommend starting screening early. For MEN1, screening should begin by age 5 and continue throughout life, with yearly blood tests adjusted by age. For MEN2A, genetic testing of at-risk children is recommended before age 5. For MEN2B, screening for pheochromocytoma begins around age 11.
Children who test positive for MEN2 mutations are typically offered preventive thyroid removal, since medullary thyroid cancer develops in virtually all carriers. The timing of this surgery depends on the specific mutation and how aggressive the cancer risk is. For MEN2B carriers, surgery is recommended as early as possible, ideally in infancy, because the cancer can develop and spread rapidly in the first years of life.
Long-Term Management
MEN syndromes require lifelong monitoring because new tumors can develop at any point. Even after successful treatment of one tumor, the underlying genetic mutation means other glands remain at risk. Recurrences can happen up to 20 years after initial treatment.
For MEN1, annual surveillance includes blood tests for calcium, parathyroid hormone, gastrin, insulin, blood sugar, prolactin, and other markers. Abdominal imaging for pancreatic and adrenal tumors is done yearly, pituitary MRI every 3 to 5 years, and chest imaging for certain rare tumors every 1 to 2 years. Treatment of individual tumors varies: some are removed surgically, while small, nonfunctioning tumors may simply be watched.
For MEN2, ongoing monitoring focuses on checking for pheochromocytoma recurrence and, if the thyroid has already been removed, ensuring thyroid hormone replacement stays adequate. Calcitonin levels (a marker produced by medullary thyroid cancer cells) are tracked to catch any recurrence. When calcitonin levels are markedly elevated or diarrhea develops, it can signal advanced or widespread disease and generally carries a worse outlook.
The prognosis varies widely depending on the type and how early it’s caught. MEN2A treated with timely surgery has a 10-year survival rate of about 92 percent. MEN1 patients can live long, relatively normal lives with proper surveillance and management of individual tumors. MEN2B remains the most challenging, but outcomes have improved dramatically since the introduction of early genetic testing and preventive thyroidectomy in childhood.